SeaSpine continues to broaden its orthobiologic offerings, receiving FDA 510(k) clearance to market OsteoBallast™ Demineralized Bone Matrix (DBM) in Resorbable Mesh. Limited launch will occur by year-end, with full commercial launch slated for mid-2018.
OsteoBallast comprises 100% DBM with no carrier, and is designed to deliver bone graft in posterior spine surgery. The product joins other biologic offerings such as OsteoStrand™ Demineralized Bone Fibers and the well-established Accell Bone Matrix. RAPID Graft Delivery, alpha-launched in 2Q17, is slated for full commercial launch in January 2018, with improvements based on feedback.
SeaSpine continues to broaden its orthobiologic offerings, receiving FDA 510(k) clearance to market OsteoBallast™ Demineralized Bone Matrix (DBM) in Resorbable Mesh. Limited launch will occur by year-end, with full commercial launch slated for mid-2018.
OsteoBallast comprises 100% DBM with no carrier, and is designed to deliver bone graft in...
SeaSpine continues to broaden its orthobiologic offerings, receiving FDA 510(k) clearance to market OsteoBallast™ Demineralized Bone Matrix (DBM) in Resorbable Mesh. Limited launch will occur by year-end, with full commercial launch slated for mid-2018.
OsteoBallast comprises 100% DBM with no carrier, and is designed to deliver bone graft in posterior spine surgery. The product joins other biologic offerings such as OsteoStrand™ Demineralized Bone Fibers and the well-established Accell Bone Matrix. RAPID Graft Delivery, alpha-launched in 2Q17, is slated for full commercial launch in January 2018, with improvements based on feedback.
Copy to clipboard 
